Oncology Venture har bekräftat registreringsstrategin för dovitinib och utvecklat ny DRP-kombinationsbiomarkör för PD1 / PD-L1 + dovitinib – inleder utlicensieringsaktiviteter med Destum Partners

Bud Bilanich
Success Coach

David Linetsky
Point-of-Care Marketing

Stacey Gandler
Brand Nourishment

Matthew Durham
Omnidynamic Marketing

Pat Purcell
Meeting Engagement

Liz Kane
Impactful Strategy

Matt Turner
Patient Affordability

Paul Theisen
Patient Acquisition

Daniel Sontupe
Market Access

Joey Cohen
Medication Adherence

Amy Giles
Increasing Engagement

Brenda Snow
Authentic Patient Voice

Frank Burrell
Scientific Storytelling

Suma Ramadas, PhD
Medical Affairs